GlassScriptPhysician profile
Peter Michael Deleeuw
NPI 1710411541
$3,388.57
in general payments reported to CMS, 2019-2025
18 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.22 · 2023: $481 · 2024: $1,054 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350 · Education: $15.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.30 |
| Education | $15.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.08 | 2023-2025 | Linzess, Viberzi, Mavyret |
| Madrigal Pharmaceuticals | $653.97 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $407.76 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $322.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.84 | 2022-2025 | Entyvio |
| Qol Medical, LLC | $191.96 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $170.09 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $153.51 | 2024-2025 | |
| Medtronic, INC. | $132.09 | 2024 | Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.37 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $110.56 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $38.76 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $38.11 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $29.92 | 2023-2024 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $17.17 | 2025 | Iqirvo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $16.59 | 2025 | Zenpep |
| Celltrion USA INC. | $15.05 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $14.73 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Deleeuw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.